Exagen to Announce Second Quarter Financial Results on August 4, 2026
Rhea-AI Summary
Exagen (Nasdaq: XGN) will release its financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. Management will host a conference call at 8:30 a.m. ET (5:30 a.m. PT), with live webcast and replay access via the Exagen investor relations website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report: XGN +3.85% in the Jul 21 session
In the Jul 21 session, XGN gained 3.85%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Earnings date | Neutral | +1.5% | Announced May 11 release date and management conference call details |
| Feb 24 | Earnings date | Neutral | -0.3% | Announced March 10 fourth-quarter and full-year results release |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings-date announcements produced mixed reactions, with moves of 1.48% and -0.27% and an average move of 0.6%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) that morning to review the Company’s results.
Conference Call and Webcast:
- U.S. dial-in: 877-407-0890
- International dial-in: +1 201-389-0918
- Webcast: Available via the Exagen Investor Relations website at investors.exagen.com
Replay: A telephone replay will be available until Tuesday, August 18, 2026:
- U.S. replay: 877-660-6853
- International replay: +1 201-612-7415
- Replay passcode: 13760979
- Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen Investor Relations website at investors.exagen.com
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Contact
Tina Jacobsen, CFA
Exagen Inc.
ir@exagen.com
